Major drivers influencing adherence and quality of life during antiviral triple therapy in patients with chronic hepatitis C

Open access


Background & Aims. Triple therapy with Peg-IFNs, Ribavirin and protease inhibitors raise the treatment success for hepatitis C up to 83%, but also bring together with the significantly higher rates of sustained virologic response (SVR) more side effects, interfering with patient’s quality of life (QoL) and work productivity. We aimed to analyze the factors influencing the adherence and the QoL during triple therapy using Peg-IFNs, Ribavirin and protease inhibitors in 50 patients diagnosed with chronic hepatitis C with first line therapy failure. Multivariate Cox proportional hazards regression was used to analyze determinants of retreatment initiation and treatment compliance, according to patient features. Results: We identified as major drivers of retreatment initiation the younger age, the female gender, the urban provenience, the high income, and the psychiatric and alcohol or drugs abuse history. The adherence and the QoL during retreatment therapy were similar, despite the regimen used, and obvious lower in patients with history of previous abandon, drugs and alcohol abuse or hematologic/ psychiatric decompensation. A lower capacity to work and a temporary withdrawal from job necessary to continue the therapy were seen similar in patients taking Boceprevir/Telaprevir. Abandon of therapy without a known reason was more frequent in males, with alcohol and drugs intake history, from rural region, with low income, and with psychiatric disturbances in personal history. Conclusion. Physicians should focus to develop medical strategies or drugs to increase the adherence and to provide a better QoL for patients with chronic hepatitis C making antiviral therapy.

1. WHO. (1999). Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 6(1), 35-47.

2. McHutchison, J.G., Manns, M.P., Muir, A.J., Terrault, N.A., Jacobson, I.M., Afdhal, N.H., Heathcote, E.J., Zeuzem, S., Reesink, H.W., Garg, J., Bsharat, M., George, S., Kauffman, R.S., Adda, N., Di Bisceglie, A.M. & Team, P.S. (2010). Telaprevir for previously treated chronic HCV infection. N Engl J Med. 362(14), 1292-1303. doi: 10.1056/NEJMoa0908014.

3. Muir, A.J., Poordad, F.F., McHutchison, J.G., Shiffman, M.L., Berg, T., Ferenci, P., Heathcote, E.J., Pawlotsky, J.M., Zeuzem, S., Reesink, H.W., Dusheiko, G., Martin, E.C., George, S., Kauffman, R.S. & Adda, N. (2011). Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 54(5), 1538-1546. doi: 10.1002/hep.24549.

4. Perry, C.M. (2012). Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs. 72(5), 619-641. doi: 10.2165/11208370-000000000-00000.

5. Ascione, A. (2012). Boceprevir in chronic hepatitis C infection: a perspective review. Ther Adv Chronic Dis. 3(3), 113-121. doi: 10.1177/2040622312441496.

6. Leroy, V., Serfaty, L., Bourliere, M., Bronowicki, J.P., Delasalle, P., Pariente, A., Pol, S., Zoulim, F., Pageaux, G.P. & French Association for the Study of the, L. (2012). Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver Int. 32(10), 1477-1492. doi: 10.1111/j.1478-3231.2012.02856.x.

7. Matthews, S.J. & Lancaster, J.W. (2012). Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clin Ther. 34(9), 1857-1882. doi: 10.1016/j.clinthera.2012.07.011.

8. Claxton, A.J., Cramer, J. & Pierce, C. (2001). A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 23(8), 1296-1310.

9. Buring, S.M., Winner, L.H., Hatton, R.C. & Doering, P.L. (1999). Discontinuation rates of Helicobacter pylori treatment regimens: a metaanalysis. Pharmacotherapy. 19(3), 324-332.

10. Connor, J., Rafter, N. & Rodgers, A. (2004). Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 82(12), 935-939. doi: /S0042-96862004001200010.

11. Iskedjian, M., Einarson, T.R., MacKeigan, L.D., Shear, N., Addis, A., Mittmann, N. & Ilersich, A.L. (2002). Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a metaanalysis. Clin Ther. 24(2), 302-316.

12. Richter, A., Anton, S.F., Koch, P. & Dennett, S.L. (2003). The impact of reducing dose frequency on health outcomes. Clin Ther. 25(8), 2307-2335.

13. Yildiz, A., Pauler, D.K. & Sachs, G.S. (2004). Rates of study completion with single versus split daily dosing of antidepressants: a metaanalysis. J Affect Disord. 78(2), 157-162.

14. van Dulmen, S., Sluijs, E., van Dijk, L., de Ridder, D., Heerdink, R. & Bensing, J. (2007). Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 7, 55. doi: 10.1186/1472-6963-7-55.

15. Special report: interventions to improve patient adherence with medications for chronic cardiovascular disorders. (2003). TEC Bull (Online). 20(3), 30-32.

16. DiMatteo, M.R. (2004). Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 42(3), 200-209.

17. Vergouwen, A.C., Bakker, A., Katon, W.J., Verheij, T.J. & Koerselman, F. (2003). Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry. 64(12), 1415-1420.

ARS Medica Tomitana

The Journal of "Ovidius" University of Constanta

Journal Information


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 145 145 7
PDF Downloads 50 50 6